Cargando…
Tumor-Cell–Macrophage Fusion Cells as Liquid Biomarkers and Tumor Enhancers in Cancer
Although molecular mechanisms driving tumor progression have been extensively studied, the biological nature of the various populations of circulating tumor cells (CTCs) within the blood is still not well understood. Tumor cell fusion with immune cells is a longstanding hypothesis that has caught mo...
Autores principales: | Manjunath, Yariswamy, Porciani, David, Mitchem, Jonathan B., Suvilesh, Kanve N., Avella, Diego M., Kimchi, Eric T., Staveley-O’Carroll, Kevin F., Burke, Donald H., Li, Guangfu, Kaifi, Jussuf T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084898/ https://www.ncbi.nlm.nih.gov/pubmed/32182935 http://dx.doi.org/10.3390/ijms21051872 |
Ejemplares similares
-
Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses
por: Suvilesh, Kanve N., et al.
Publicado: (2022) -
(18)F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer
por: Avella, Diego M., et al.
Publicado: (2020) -
PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer
por: Manjunath, Yariswamy, et al.
Publicado: (2019) -
Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer
por: Nussbaum, Yulia I., et al.
Publicado: (2021) -
Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)